Standout Papers

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 tr... 2018 2026 2020 2023 343
  1. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial (2018)
    Daniel J. Wallace, Richard Furie et al. The Lancet

Immediate Impact

1 from Science/Nature 58 standout
Sub-graph 1 of 21

Citing Papers

Therapeutic advances in rheumatoid arthritis
2024 Standout
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
1 intermediate paper

Works of Tara Carmack being referenced

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
2018 Standout
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
2018

Author Peers

Author Last Decade Papers Cites
Tara Carmack 369 87 65 196 138 9 483
C A Wijbrandts 362 69 78 152 71 7 538
Rahul Patel 204 108 47 220 72 11 515
N. T. CHEUNG 288 143 33 186 117 9 568
Sybille Arnold 274 48 44 190 50 13 439
Sylke Kaltenhäuser 266 51 49 227 50 13 495
Marjolein Vinkenoog 311 119 32 205 58 8 543
Edward J. Fudman 253 46 77 124 50 9 551
Paulina Chalan 190 48 54 175 78 16 441
Emeli Lundström 357 39 60 165 34 10 451
Wendy Douglass 245 138 88 164 30 12 482

All Works

Loading papers...

Rankless by CCL
2026